IRD logo

OPUS GENETICS INC

IRDNASDAQ
🏆 #3250 by market capUS Equity
$3.68—
Last available close · quote unavailable
🔔
Track IRD
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d▼ 3.5%
14d▼ 8.9%
30d▼ 25.5%
ytd▲ 83.5%
1y▲ 84.9%
🏦Market Cap
$306M
Small Cap
📈Revenue Growth (YoY)
-36.1%
Declining
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
31.1x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
—
52-Week Range
$1.70 – $7.07
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
83.2M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$14M
Last Q Revenue
$755,000
P/E Ratio
—
P/S Ratio
31.1x
EPS (TTM)
$-1.29
Dividend Yield
—
Dilution (1yr)
+1870.6%
IRD logo

OPUS GENETICS INC

IRD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$14M▲ +29.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$39M▼ −37.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$35M▲ +37.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
622.2M▲ +1870.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$45M▲ +$15M YoY
StockOtter · stockotter.space

About OPUS GENETICS INC

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.